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Abstract
Background: L1 cell adhesion molecule (CD171) is expressed in many malignant tumors and its expression
correlates with unfavourable outcome. It thus represents a target for tumor diagnosis and therapy. An earlier study
conducted by our group identified L1 expression levels in primary gastrointestinal stromal tumors (GIST) as a
prognostic marker. The aim of the current study was to compare L1 serum levels of GIST patients with those of
healthy controls and to determine whether levels of soluble L1 in sera could serve as a prognostic marker.
Methods: Using a sensitive enzyme-linked immunosorbent assay (ELISA), soluble L1 was measured in sera of 93
GIST patients und 151 healthy controls. Soluble L1 levels were then correlated with clinicopathological data.
Results: Median levels of soluble L1 were significantly higher (p < 0.001; Mann-Whitney U test) in sera of GIST
patients compared to healthy individuals. Median soluble L1 levels were particularly elevated in patients with
recurrence and relapse (p < 0.05; Mann Whitney U test).
Conclusion: These results suggest that high soluble L1 levels predict poor prognosis and may thus be a promising
tumor marker that can contribute to individualise therapy.
Keywords: Gastrointestinal stromal tumor (GIST), L1, Enzyme-linked Immunosorbent assay (ELISA), progression
marker
Background
Gastrointestinal stromal tumors (GIST) are the most
common gastrointestinal mesenchymal tumors with an
incidence of 10-13 per million people a year [1]. They are
mostly discovered incidentally during endoscopic or sur-
gical procedures or are diagnosed in the evaluation of
patients suffering from abdominal pain or/and upper gas-
trointestinal bleeding. GISTs occur most frequently in
the stomach and small intestine, but rarely in the esopha-
g u sa n dc o l o r e c t u m[ 2 , 3 ] .G I S T sa r et h o u g h tt oa r i s e
from common precursor cells of the interstitial cells of
Cajal (ICC) from the muscular plexus in the gut wall [4].
Following the consensus approach of 2002, they are
classified according to tumor size and mitotic index [5].
After surgical resection the outcome of GIST is corre-
lated with size and mitotic count and patients with recur-
rence have a worse prognosis [6]. Activating mutations in
t h et y r o s i n ek i n a s ec-kit (CD117) gene and platelet-
derived growth factor receptor a gene (PDGFRa)h a v e
been reported to play important roles in the progression
and diagnosis of GISTs [7,8]. First line therapy for
unresectable or metastatic GISTs by molecular targeting
with the tyrosine kinase inhibitor imatinib (Glivec
®)h a s
been shown in clinical trials to be efficacious and well
tolerated [9].
T h e r ei st od a t en op r o g n o s t i cs e r u mm a r k e rf o r
GISTs. One possible candidate is the neuronal cell adhe-
sion molecule L1 (CD171), which is expressed in pri-
mary tumors in 74% of cases [10]. L1 is a 200-220 kDa
multidomain type 1 membrane glycoprotein of the
immunoglobulin superfamily which plays a central role
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plasticity in the adult nervous system [11,12]. It affects
neuron-neuron adhesion and neurite outgrowth on
Schwann cells as well as neurite fasciculation and myeli-
nation [13]. The extracellular domain of L1 can be regu-
latorily cleaved from the tumor cell surface in a process
called shedding. Several L1 processing proteases could
be identified such as members of a disintegrin and
metallprotease ADAM10, ADAM17 [14,15] and PC5A
[16]. The shed and solubilised extracellular domain is
able to mediate L1 signal transduction via homo- and
heterophilic interactions [17]. Among others L1 binds
integrins and other members of the L1 family, such as
CHL1 and NrCAM [18-20].
L1 overexpression has been detected in various tumor
cell types of neural, mesothelial, and epithelial origin.
Expression profile analysis in multiple human tumors
has identified L1 as a molecular marker for differential
diagnosis and targeted therapy [21,22]. Its presence in
tumors and sera has a prognostic significance in ovarian,
uterine and renal cell carcinomas and is associated with
metastasis of melanomas [23-25].
The aim of this study was to evaluate whether soluble
L1 could serve as diagnostic marker and prognostic fac-
tor in GIST patients by correlating L1 serum levels to
long-term outcome.
Methods
Study design and patients
The study was approved by the Ethics Committee of the
Chamber of Physicians in Hamburg, Germany. Written
informed consent was obtained from all patients for
using tissue and serum samples. For this study, 93
patients with GIST were chosen retrospectively. It was
possible to evaluate a rather large number of patients
suffering from this rare tumor because of the coopera-
tion of a self-help organization for GIST patients called
“Lebenshaus e.v.”,B a dN a u h e i m ,G e r m a n y ,w h i c h
helped to collect serial serum samples from patients
across Germany, Austria and Switzerland. The blood
samples were taken from patients at time of diagnosis
and every 3 months thereafter. We selected patients on
the basis of availability of specimens and did not stratify
them due to rare occurrence and different treatment
strategies. All data including sex, age, tumor size, mito-
tic count, tumor location, metastasis, relapse, and imati-
nib therapy were obtained from the clinical and
pathological records. The clinicopathological data from
externally treated patients participating in the self-help
project were sent regularly by their attending physicians.
As healthy controls, 151 blood bank donors were
included in the study. Limitations in this study were
that we had some missing items in the clinical and
pathological data of our patients due to logistic
difficulties in collecting data of patients from different
hospitals. However, a sufficient number of GIST patients
were included in the study.
ELISA for the detection of soluble human L1
For the detection of soluble L1, 96-well flexible microti-
ter plates (Costar 9019) were coated with 50 μl per well
of 10 μg/ml of capturing antibody (anti-L1 mAb 5G3,
BD Bioscience) overnight at 4°C. Wells were blocked
with 3% w/v bovine serum albumin (BSA; Fraktion V,
98% purity, Sigma Aldrich, Munich, Germany) in PBS/T
(phosphate buffered saline, pH 7.3, containing 0.05% v/v
Tween) for 45 min at room temperature and then incu-
bated for 1 h with human sera diluted 1:5 in PBS at
room temperature. After five washes with PBS/T, bound
protein was detected with biotin-conjugated monoclonal
antibody UJ127 (Dianova, Hamburg, Germany)- which
does not cross-react with the close homolog of L1
(chL1) - followed by streptavidin-conjugated peroxidase
using TMB (3,3’, 5,5"-tetramethylbenzidine) as substrate.
The color reaction was stopped by the addition of 10
mM H2SO4 and analysed at 450 nm using an ELISA
reader. Human L1-Fc protein served as an internal stan-
dard for the assay.
To ensure that the immunoassay was suitable for mea-
suring clinical serum samples, reproducibility, linearity
and crossreactivity were examined. The assay showed no
crossreactivity with the closed homolog of L1 CHL1,
excellent linearity with serial dilutions and a low coeffi-
cient of variation (CV) in intra- and inter-assay
variability.
Sample preparation and Western blot analysis
For analysis of L1cam protein, PBS washed GIST882
cells were lysed in RIPA buffer (50 mM Tris-HCl, 150
mM NaCl, 1 mM Na4P2O7, 1 mM NaF, 1 mM EDTA, 2
mM Na3VO4,1m MP M S F ,1 %N P - 4 0p l u sc o m p l e t e
EDTA-free protease inhibitor mixture, pH 7.5) for 30
min at 4°C and then subjected to SDS-Page and Wes-
tern blot analysis. Equal amount of protein of each sam-
ple was mixed with 2x Laemmli Buffer (4% SDS, 20%
glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol
b l u e ,0 . 1 2 5MT r i sH C l ,p H6 . 8 )a n db o i l e da t9 5 ° Cf o r
5 min. Protein extracts were separated by 4 - 12% SDS-
PAGE (NuPage, Invitrogen, Karlsruhe, Germany) and
transferred onto nitrocellulose membrane (Protran;
Whatman Schleicher and Schuell Dassel, Germany). For
immunoblotting, membranes were blocked with Star-
tingBlock (TBS) Blocking Buffer (Pierce, Rockford, IL,
U S A )a n di n c u b a t e do v e r n i g h ta t4 ° Cw i t hp r i m a r y
1:1000 biotinylated antibody L1-UJ127 (Dianova, Ham-
burg Germany). UJ127 binds to a membrane proximal
Fn repeat. This allows detection of both the ADAM-
cleaved 180 kDa shed fragment and the 80 kDa
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plasmin cleavage. After washes with TBST (TBS with
0.1% Tween 20), membranes were incubated with HRP-
conjugated streptavidin (Sigma Aldrich, Munich, Ger-
many) (1:500) for 1 h at room temperature. After exten-
sive washes, streptavidin-reactive bands were visualized
using enhanced chemiluminescent substrate (ECL,




® for Windows (Version 11.5.1) (SPSS
® Inc., Chi-
cago, IL, USA) was used for statistical analysis. Statisti-
cal significance was evaluated by the Mann-Whitney U
and Kruskal-Wallis test. Cross-table statistics were per-
formed using Fisher’s test. Recurrence-free survival was
plotted using the Kaplan-Meier method and analysed by
the log-rank test. Significance statements refer to p-
values of two-tailed tests less than 0.05.
Results
Characteristics of patients and healthy controls
A total of 93 patients suffering from GIST and 151
apparently healthy controls were included in our study.
The median age of GIST patients was 61 years (range
28-81 years) and 47 years (range 30-70 years) for the
healthy controls. Fifty-one (55%) of the GIST patients
were male and 42 (45%) female, Ninety-eight (65%) of
the healthy controls were male and 53 (35%) female.
Patients` characteristics and clinicopathological data are
listed in Table 1.
Soluble-L1 concentrations of healthy controls and GIST
patients
L1 could be detected in sera of GIST patients, represen-
tatively shown in Figure 1. In sera proteolytically cleaved
soluble L1 fragments as well as full-length L1 were spe-
cifically recognised by the monoclonal antibody UJ127,
which was also used in the ELISA, underlining the spe-
cificity of the assay. Lysate of the cell line GIST882 [26]
was used to visualise membrane bound or associated L1
compared to soluble cleavage products. In patient sera,
the shed extracellular domain of 180 kDa, generated by
cleavage of ADAM10/17, is detectable but not the 80
kDa form generated by PC5 or Plasmin.
Soluble L1 (s-L1) concentrations in the sera of GIST
patients were significantly higher than in healthy con-
trols: median (25th and 75th percentiles) soluble L1
values were 1.4 (0.8 and 2.7 respectively) ng/ml in the
GIST patients and 0.5 (0 and 1 respectively) ng/ml in the
controls (p < 0.001; Mann-Whitney U test) (Figure 2).
The mean (± SD) soluble L1 concentration was 2.1 ± 2.5
ng/ml for GIST patients and 0.7 ± 1.4 ng/ml for healthy
controls. Detailed clinicopathological data are given in
Table 1. In addition s-L1 levels were not elevated in
other benign and malignant gastic tumors (n = 59, data
not shown). There was no influence of sex, age, tumor
size, mitotic count, tumor location, resection margin or
imatinib treatment on soluble L1 concentrations.
Increased soluble L1 serum concentrations correlate with
recurrence and negative outcome
Table 1 shows that GIST patients with recurrence had
significantly higher median soluble L1 concentrations
than those without. Soluble L1 concentration (25th and
75th percentiles) was 1.7 (0.9 and 3) ng/ml in GIST
patients with recurrence and 1.1 (0.8 and 1.7) ng/ml in
relapse-free patients (p = 0.049; Mann-Whitney U test).
The median follow-up time in the study was 37
months (range 0-273 months). For additional statistical
analysis, patients with high (>2 ng/ml) and low (<2 ng/
ml) soluble L1 concentrations were compared by survi-
val curves plotted by the Kaplan-Meier method for
recurrence-free survival (Figure 3). GIST patients with
high soluble L1 levels showed a significantly worse out-
come (38 months [95%-CI: 27; 50] of recurrence-free
survival compared to 73 months [95%-CI: 56; 90] in
patients with low soluble L1 levels (p = 0.016, log-rank
test). Accordingly, the five-year recurrence-free survival
rate among patients with low soluble L1 levels was 52%,
while it was only 19% in patients with high soluble L1
levels. Absolute recurrence counts were significantly
higher in patients with high soluble L1-levels (p = 0.025,
Fischer’st e s t ,d a t an o ts h o w n ) .W er e f r a i n e df r o ma n a -
lysing overall survival because of low numbers (n = 4)
of deaths in the patient group in this study.
Neither mitotic count nor tumor size had an influence
on recurrence-free survival plotted by Kaplan-Meier
analyses (p = 0.231 and p = 0.199, log rank test; data
not shown). Also mitotic count and tumor size could
not be significantly correlated with recurrence (p =
0.075 and p = 0.725, Fisher’s test).
Discussion
Most primary cancers develop loss of expression of
adhesion molecules. This allows for a critical step in
metastasis to occur: detachment of the invading cell
from its neighbors [27,28]. Some adhesion molecules,
such as L1, however show elevated expression in some
tumor entities. There are several potential interpreta-
tions for this phenomenon. Increased homophilic inter-
cellular adhesion may favor the metastatic process
because cell aggregates, rather than single cells breaking
away from the primary tumor, have a greater chance of
surviving in the circulation and of lodging in other
organs [29]. Furthermore it is known that cell adhesion
is necessary for the metastatic spread of cancer cells to
new organs [27]. It was shown that L1 expressed on
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genesis [30]. The development of new blood vessels is a
key step of tumor progression that might be promoted
by the interaction of proteolytically cleaved soluble
forms of L1 with integrins [31]. The shed L1 can pro-
mote L1 dependent homophil i cs t i m u l a t i o ni na na u t o -
crine fashion [32]. The proteolytic events not only take
place on the cell surface but also on membrane vesicles
such as exosomes and apoptotic membrane vesicles
[33]. This can explain the detection of full length and
shed L1 in sera.
In a previous study we could show that L1 expression
was immunohistochemically detectable in 74% of GISTs,
but not in differential diagnostic important tumors such
as smooth muscle tumor, peripheral nerve sheath tumor
or desmoid-type fibromatosis. Although c-kit expression
Table 1 Clinicopathological characteristics of GIST patients (n = 93) and soluble L1 concentrations





concentration ± SD (ng/ml)
p-value
Total
GIST 93(38) 1.4 (0.8 and 2.7) 2.1 ± 2.4
Controls 151(62) 0.5 (0.0 and 1.0) 0.7 ± 1.4 >0.001
GIST
Sex
Male 51 (54.8) 1.5 (0.8 and 2.7) 2.1 ± 2.6
Female 42 (45.2) 1.3 (0.8 and 2.4) 2 ± 2.3 0.708
Tumor size (cm)
<2 8 (11) 1.4 (0.9 and 4.8) 2.9 ± 3
2-5 21 (29) 1.7 (1 and 2.4) 2.2 ± 2.2
5-10 21 (29) 1.2 (0.7 and 2.4) 1.9 ± 2.1
>10 22 (31) 1 (0.4 and 2) 1.4 ± 1.4 0.305
Mitotic count (per 50 HPF)
<5 27 (48) 1.1 (0.6 and 1.9) 1.7 ± 2.1
5-10 8 (14) 1.1 (0.7 and 2) 1.3 ± 0.8
>10 21 (38) 1.7 (1.1 and 2.6) 1.9 ± 1.2 0.258
Tumor location
Stomach 52 (65) 1.4 (0.9 and 2.6) 2.0 ± 2.0
Small intestine 23 (29) 1.5 (0.6 and 2.6) 1.8 ± 2
Others 5 (6) 1.1 (0.5 and 3.2) 1.7 ± 1.5 0.921
Resection margin
R0 52 (76) 1.4(0.8 and 2.6) 2.1 ± 0.4
R1/2 16 (24) 1.4(1.2 and 2.6) 2.0 ± 0.4 0.529
Recurrence
No 35 (45) 1.1 (0.8 and 1.7) 1.4 ± 1.2
Yes 42 (55) 1.7 (0.9 and 3) 2.4 ± 2.3 0.049
Imatinib
No 35 (46) 1.4 (0.8 and 3.0) 2.4 ± 2.7
Yes 41 (54) 1.5 (0.7 and 2.4) 1.6 ± 1.2 0.673
Risk NIH criteria
Very low 5(9) 1.2 (0.7 and 2.8) 1.7 ± 1.4
Low 9(16) 1.1 (0.8 and 1.9) 1.4 ± 1.0
Intermediate 9(16) 0.7 (0.3 and 2.4) 2.0 ± 3.0
High 33(59) 1.5 (0.8 and 2.4) 1.7 ± 1.4 0.834
Risk AFIP criteria
Very low 5(9) 1.2 (0.7 and 2.8) 1.7 ± 1.4
Low 11(20) 1.4 (0.9 and 2.2) 1.8 ± 1.4
Intermediate 13(23) 0.7 (0.2 and 2.0) 1.9 ± 2.8
High 27(48) 1.5 (1.0 and 2.6) 1.6 ± 1.1 0.717
NIH: National Institute of Health; AFIP: Armed Forces Institute of Pathology
Not all counts add up to the full number of included patients (n = 93), due to incomplete data. P-values were calculated by the Mann-Whitney-U and Kruskal-
Wallis tests
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additional prognostic markers are beneficial. To date,
most studies regarding L1 expression have been per-
formed at the mRNA level or by immunohistochemistry.
To evaluate the role of L1 as a peripheral marker, we
here examined L1 levels in serum of GIST patients and
healthy controls.
Using a specifically developed robust and highly sensi-
tive immunoassay we were able to demonstrate that
soluble L1 concentrations were significantly elevated in
the blood of GIST patients compared to a healthy con-
trol group and other gastric tumors. Furthermore, we
observed a significant association between increased
soluble L1 levels and recurrence, which predicts worse
outcome in GIST. Patients with high soluble L1 concen-
trations had a poorer recurrence-free survival than
patients with lower levels. These observations are in
agreement with our previous immunohistochemical
study, where a trend towards worse outcome of patients
with L1-positive tumors was reported [10,34]. Elevated
soluble L1 as a negative prognostic marker has already
been shown for some types of ovarian cancers [25]. In
melanoma and ovarian carcinoma the cleaved L1CAM
ectodomain can play a role in tumor progression, con-
ferring cellular properties that are important in
advanced stages of cancer progression including
enhanced motility and invasivenes [33,35]. Our study
suggests that also in GIST, high L1 serum levels are
leading to high cell dispersal of the tumor which aug-
ments the risk of recurrence.
Soluble L1 concentration could thus become a useful
marker for tumor progression and metastasis, which
predicts prognosis in GIST.
Our results also suggest that L1 may be an important
therapeutic target in the treatment of GIST. The effi-
ciency of L1 monoclonal antibody treatment in suppres-
sing tumor growth has been described in nude mice,
where intraperitoneal injection of an L1 antibody was
Figure 1 Western blot analysis of GIST882 cell lysate compared
to a patient serum using the biotinylated antibody L1-UJ127.
Three major bands corresponding to L1 are detectable in the cell
lysate. The 220 kDa form represents the full length L1-Protein, while
L1-180 kDa and L1-80 kDa are proteolytically cleaved. L1-180 kDa
represents the shedded extracellular domain while L1-80 kDa is a
c-terminal fragment integral to the membrane. In serum, soluble
forms of L1 with the molecular weights of approx. 200 kDa and 180
kDa are detectable. The L1-80 kDa fragment is not present in sera.
Figure 2 Box-plots show medians (black lines) of soluble L1
concentrations in healthy controls (n = 151) and GIST patients
(n = 93) determined by ELISA. Statistical significance was
determined by the Mann-Whitney U test (p < 0.001).
Figure 3 Kaplan-Meier survival curve for recurrence-free
survival in GIST patients. Groups with soluble L1 concentrations
lower or higher than 2 ng/ml were compared. P-values were
calculated with the log-rank test.
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dissemination of malignant tumor cells [36]. In this con-
text it might be relevant that soluble L1 levels depend
on the presence of proteinases. Matrix metalloprotei-
nases (MMPs) and a disintegrin and metalloproteinases
(ADAMs) are involved in many aspects of tumor biol-
ogy. ADAM17, which has been shown to mediate L1
cleavage [15] has also been identified as a major shed-
dase in GIST [37].
Concusions
We provide evidence that analysis of serum concentra-
tions of soluble L1, comprising the extracellular domain
of the L1 molecule, represents a novel and useful
approach to assess the malignancy and metastatic poten-
tial of GISTs. The availability of a reliable immunoassay,
such as the one developed for this study, for measuring
serum L1 concentrations will facilitate further studies to
establish the clinical applicability of this marker in
GISTs and other tumors. These studies should notably
investigate L1 levels in other serum samples such as
obtained pre- and post-surgery and serially during the
course of therapy. Beyond clinical applicability, future
work must address mechanistic questions about the
functional role of L1 in the tumorigenesis of GISTs and
other L1 expressing cancers.
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